Scilex Acquires Rights for Elyxyb to Treat Migraine in the US and Canada
- Scilex, a majority-owned subsidiary of Sorrento Therapeutics acquires rights to Elyxyb (celecoxib oral solution), a ready-to-use oral solution for the acute treatment of migraine with/out aura in adults in the US and Canada
- Additionally, the acquisition expands Scilex’s non-opioid portfolio in broader acute pain indications with the addition of Elyxyb & also establishes a growth platform for Scilex and fits within Scilex’s existing commercial team
- In the pivotal studies, Elyxyb demonstrated a rapid onset of action for patients suffering from acute migraine attacks & celecoxib was found to be effective at treating migraines with few AEs
Ref: Globenewswire | Image: Scilex
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.